[Current news in prophylaxis and malaria treatment (author's transl)].
The extension of chloroquines resistance of Plasmodium falciparum, the emergence, still limited, of resistance to pyrimethamine-sulfadoxine, and even of multi-resistant strains, are facts all the more disturbing--especially for South East Asia--that the number of antimalarials is limited. Mefloquine appears to be a very promising drug; it might perhaps be desirable to be able to combine it with a new antimalarial, in collective prophylaxis, to prevent the selection of possibly resistant strains.
D000962:Antimalarials / Q000627:therapeutic use*; D002738:Chloroquine / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D015767:Mefloquine; D010963:Plasmodium falciparum / Q000187:drug effects; D011804:Quinolines / Q000627:therapeutic use*
D000962:Antimalarials; D011804:Quinolines; D002738:Chloroquine; D015767:Mefloquine
Actualités dans la prophylaxie et le traitement du paludisme.